Industry News (Infection Control)

Phase I Trial Begins in U.S. for Bloodstream Infection Prevention

Published in Blood Weekly, December 21st, 1998

Micrologix Biotech, Inc., Vancouver, British Columbia, announced that it has initiated a Phase I human clinical trial of MBI 226, its lead antimicrobial peptide, for the prevention of bloodstream infections in patients undergoing central venous catheterization.

Bloodstream infections resulting from intravenous catheters are a serious medical problem. The U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, estimates that in the U.S. alone, 250,000 hospitalized patients contract bloodstream infections each year. These infections most commonly derive from the use of invasive devices such as intravenous catheters. More than 90 percent of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry